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Abstract
Both rectal and vaginal mucosal surfaces serve as transmission routes for pathogenic 
microorganisms. Vaccination through large intestinal mucosa, previously proven protective for 
both mucosal sites in animal studies, can be achieved successfully by direct intra-colorectal (i.c.r.) 
administration, which is, however, clinically impractical. Oral delivery seems preferable, but risks 
vaccine destruction in the upper gastrointestinal tract. Therefore, we designed a large intestine-
targeted oral delivery with pH-dependent microparticles containing vaccine nanoparticles, which 
induced colorectal immunity in mice comparably to colorectal vaccination and protected against 
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rectal or vaginal viral challenge. Conversely, vaccine targeted to the small intestine induced only 
small intestinal immunity and provided no rectal or vaginal protection, demonstrating functional 
compartmentalization within the gut mucosal immune system. Therefore, using this oral vaccine 
delivery system to target the large intestine, but not the small intestine, may represent a feasible 
novel strategy for immune protection of rectal and vaginal mucosa.
INTRODUCTION
Mucosal immunization has proven to be critical to induce mucosal protection1–5 and 
contributes to rapid and long-lasting mucosal protection in contrast to systemic 
immunization6. It has been shown that antigen-specific functional CD8+ cytotoxic T cells in 
the mucosa are critical to protect from CD4+ T cell depletion by SHIV3, while human 
studies indicate that a higher frequency of the antigen-specific mucosal CD8+ T cells 
correlates with a lower degree of herpes simplex viral infectivity as well as reduced severity 
of the disease7. In the mucosal tissues of HIV-infected long-term nonprogressors, there exist 
immunodominant CD8+ T cells and their presence is strongly correlated with HIV-1 
control5,8. A variety of approaches have been proposed and employed to induce protective 
mucosal immunity against viral transmission through either the rectal or vaginal 
route1–3,9–11. However, potent but clinically practical genitorectal vaccination strategy 
remains unestablished for the following reasons.
Large intestinal mucosa is an optimal site to induce both rectal and vaginal immunity. Intra-
colorectal (i.c.r.) vaccination directly at the large intestinal mucosa induces robust cellular 
and humoral immune responses in the regional lymph nodes4, more effectively than 
vaccination at a distant mucosa (e.g., intranasal) or by a parenteral route1–5. However, for 
mass human vaccination, i.c.r. administration appears to be clinically too cumbersome and 
unpalatable. In addition, this procedure could potentially be traumatic without adequate 
caution. Given that the intranasal route, although practical and relatively easy, poses the risk 
of inoculum invasion into the central nervous system by olfactory nerve transport12, a truly 
safe vaccine delivery route is needed. The oral route is the safest and most practical. 
However, except for a few live attenuated vaccines inducing systemic responses, simple oral 
delivery is ineffective at protecting either rectal or genital mucosa13. The failure is mostly 
attributed to the enzymatic destruction in the proximal gut and likely inadequate antigen 
uptake in the large intestine.
We here aimed to discover a way to selectively deliver a vaccine to the large intestinal 
mucosa through the oral route, which has not previously been accomplished. To mimic the 
“gold standard” i.c.r. immunization while circumventing the limitations of oral delivery, we 
encapsulated a peptide or protein vaccine into biologically compatible poly(DL-lactic-co-
glycolic acid) (PLGA) nanoparticles14,15 to be used for site-specific immunization. The 
depot effect of PLGA nanoparticles offers an additional feature that controlled release of 
entrapped vaccines over extended time periods provides a longer antigen exposure to the 
immune system. PLGA particle size, adjustable during manufacturing, was engineered in 
nanometers because size-dependent mucosal uptake is most effective within nanometer 
ranges and impeded when the size is over 1 micron16. Selective combinations of TLR 
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ligands can induce synergistic activation of T cells17–19. We adjuvanted the vaccine with 
MALP-2, poly(I:C) and CpG ODN, which have been shown to synergistically induce 
mucosal anti-viral protection after i.c.r. immunization20.
To bypass the harmful effects of digestive low pH and enzymatic destruction and to 
selectively deliver the particles to the lower gastrointestinal (GI) tract intact, the PLGA 
nanoparticle surface was coated with methacrylate-based polymer Eudragit FS30D21, an 
anionic tripolymer comprising poly(methyl acrylate, methyl methacrylate, methacrylic acid) 
in a 7:3:1 ratio. The ratio of free carboxyl groups to ester groups is ~1:10. It is pH sensitive 
and soluble in intestinal fluids at pH > 7.0, seen only in the terminal ileum, thereby 
preventing contents from degradation more proximally. These coated particles are ≥ 10 
micrometers in diameter in order to avoid premature uptake in the small intestine primarily 
by Peyer’s patches, which can significantly take up particles up to 1 μm16. Our design is 
shown in Supplementary Fig. 1.
RESULTS
Proof of principle study on the PLGA nanoparticle vaccine
Uncoated PLGA nanoparticles were manufactured in the range from 300 500 nm (418 nm ± 
88 SD) (Supplementary Fig. 2a), with 90% encapsulation efficacy (Supplementary Fig. 2b). 
We first conducted a proof of principle experiment in which fluorescent fluorescein-
containing PLGA/FITC-BSA nanoparticles were delivered directly to the colon of mice by 
i.c.r. administration. At day 3, a proportion of the cells isolated from the large intestinal 
lamina propria were detected positive for fluorescence expression (Fig. 1a), indicating an 
uptake of the nanoparticles. Nanoparticle uptake was primarily found in CD11b+B220int 
macrophages and secondarily in CD11c+CD11b+ dendritic cells (DCs) in the lamina propria 
of the large intestine (Supplementary Fig. 3a). Transmission electron microscopy indicates 
PLGA nanoparticles in the cytoplasm (Supplementary Fig. 3b). Uptake of PLGA 
nanoparticles by DCs (derived from bone marrow) was also confirmed in vitro by flow 
cytometry (Supplementary Fig. 4a), fluorescence microscopy (Supplementary Fig. 4b) and 
transmission electron microscopy (Supplementary Fig. 4c).
We subsequently confirmed that antigen-specific T cells responses could be induced in the 
colon after a single i.c.r. delivery (Fig. 1b), but not after s.c. administration (Supplementary 
Fig. 5), of PLGA nanoparticles encapsulating PCLUS3-18IIIB (CD4+ T cell helper epitopes 
fused with HIV Env CD8+ CTL epitope) and TLR ligands (MALP2+poly(I:C)+CpG)20. 
Therefore, PLGA nanoparticles can serve as an effective vaccine delivery system when they 
are deposited in the large intestinal lumen.
Oral delivery of nanoparticle-releasing microparticle vaccines
The Eudragit served to make 10 50 μm particles and released contents substantially as early 
as 1 h at pH 7.4, in contrast to at pH 2.5 at which the particles were stable (Supplementary 
Fig. 6). After oral delivery of Eudragit FS30D containing PLGA/FITC-BSA nanoparticles, 
nanoparticle uptake was found almost exclusively in the large intestine (Fig. 1c,d). The 
cecum is the first part of the large intestine encountered, but in humans, where the cecum is 
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relatively small, the balance between cecum and colon may be different. We further 
contrasted FS30D with L100-55 microparticles containing the same nanoparticles for lower 
pH release (pH > 5.5) in the small intestine and found that oral administration of Eudragit 
L100-55-coated nanoparticles resulted in primary uptake rather in the small intestine (Fig. 
1c,d). Likewise, uncoated PLGA nanoparticles, to the extent any successfully traversed the 
stomach, were primarily delivered to the small intestine (Supplementary Fig. 7). Thus, the 
distribution of nanoparticles was altered by coating them with FS30D, such that a majority 
now reached and were taken up by cells in the large intestine (Fig. 1c,d and Supplementary 
Fig. 7). These results validate the approach of coating PLGA nanoparticles with FS30D to 
protect them during transit through the upper GI tract for increased delivery to the large 
intestine.
We next used a luciferase reporter system to confirm the large intestine targeted delivery 
with FS30D. Luciferase expression was measured in intestinal sections after oral 
administration of FS30D/PLGA containing a luciferase DNA plasmid (Supplementary Fig. 
8).
After confirming that formulated vaccine components within the micro/nanoparticles 
retained TLR agonist activity in in vitro settings or after oral administration (Fig. 2a), we 
examined intestinal immune responses in mice after two immunizations with the two 
different Eudragit coatings of the PLGA nanoparticle vaccine given orally with a two-week 
interval. Three weeks after the second immunization, tetramer positive CD8+ T cells were 
detected in the large intestine, indicating successful induction of colorectal immunity with 
the oral FS30D-coated vaccine (Fig. 2b,c). In contrast, the L100-55-coated vaccine induced 
a minimal level of colonic antigen-specific CD8+ T cells (Fig. 2b,c). In fact, the L100-55-
coated vaccine induced a T cell response primarily in the small intestine, where the FS30D-
coated vaccine was only marginally effective (Fig. 2d). Without Eudragit coating, PLGA 
nanoparticle vaccines did not elicit significant immune responses in the large intestine but 
did induce responses in the small intestine (Fig. 2e,f). The results affirm that the enteric 
coating with FS30D is essential for oral delivery of PLGA nanoparticles to the large 
intestine.
Induction of T-cell immunity against viral infection
To evaluate the protective efficacy of this vaccine, after prime and boost oral immunization, 
we challenged mice rectally with a replication-competent vaccinia virus vPE-16, which 
expresses the HIV Env epitope P18-I10 used in the peptide vaccine. Mice immunized with 
the L100-55-coated vaccine were not protected from the virus challenge. However, the 
FS30D-coated vaccine reduced viral load almost equally as well as the peptide vaccine 
given i.c.r. (Fig. 3a). Therefore, oral delivery of FS30D-coated PLGA vaccine targeting the 
large intestine is effective for local colorectal vaccination against viral infection.
It has been previously shown that i.c.r. vaccination with adenovirus-based vaccines induced 
effective protection against virus challenge (vaccinia and HSV-2) not only in the rectal but 
also in vaginal mucosa4. To determine whether vaginal mucosal protection can be induced 
by the orally administered FS30D-coated PLGA vaccine, we immunized mice orally with 
the vaccine (FS30D/PLGA/PCLUS3-18IIIB+TLR ligands) twice with a two-week interval, 
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followed by intravaginal (i.vag.) challenge with vPE-16. Compared to i.c.r. immunization, 
oral delivery of FS30D-coated vaccine induced almost equal clearance of virus after vaginal 
challenge (Fig. 3b), whereas, again, the L100-55 formulation that delivers the vaccine to the 
small intestine was not effective. Thus, delivery to the large intestine was more effective 
than to the small intestine in protecting against both genital and rectal challenge. This 
efficacy was largely T-cell mediated, as the virus does not incorporate gp160 into virions 
and is not sensitive to anti-gp160 neutralization.
Induction of antibody immunity against viral infection
The humoral response also plays an important role in protection in the gut and genital 
mucosal immunity. Therefore, we examined whether encapsulating whole viral proteins in 
the FS30D-coated PLGA vaccine can induce antibody-mediated protective immunity at both 
mucosal sites after challenging mice with pathogenic vaccinia strain WR. Vaccinia A33 and 
L1 are immunogens of the extracellular enveloped virion and intracellular mature virion, 
respectively. Antibody responses induced by the combination of both types of viral antigens 
encoded by plasmid DNA22 or as recombinant proteins23 can protect animals from lethal 
challenge of WR. Of note, CTLs specific for the vaccinia protein A33 or L1 have not been 
reported in BALB/c mice24. TLR ligands have been shown to activate B cells directly and 
contribute to antigen-specific antibody responses25,26, including in the gut27. Here we found 
that the triple TLR ligands previously shown to synergistically activate naïve T cells20 could 
also synergistically activate B cells (Supplementary Fig. 9a) as determined by CD6928. I.c.r.. 
immunization with the combination of recombinant A33 and L1 mixed with the triple TLR 
ligands in DOTAP induced antibody responses in the blood (Supplementary Fig. 9b).
The ability of PLGA nanoparticles containing the above vaccine components to induce 
antibody responses was assessed by immunization through either the i.c.r. or s.c. routes 
(Supplementary Fig. 10a), and the results further showed that CD4+ T cells were also 
activated by such a vaccine regimen (Supplementary Fig. 10b). We therefore constructed 
FS30D-coated PLGA/A33+L1+TLRL vaccine microparticles and administered them orally. 
Vaccinia-specific IgA and IgG antibody responses were significantly induced in both the 
large intestine (tested in tissue homogenates) and vaginal tracts (tested in vaginal washes) 
(Fig. 4a). Further, orally immunized mice resisted the WR virus challenge by either the 
rectal or vaginal route (Fig. 4b) as determined by weight loss and by 0 vs 75% or 50% 
mortality, respectively. Therefore, the FS30D-coated PLGA vaccine system can also be used 
to induce antibody-mediated mucosal protection at both mucosal transmission sites.
DISCUSSION
As direct rectal or vaginal vaccine delivery may be impractical for mass human vaccination, 
despite the efficacy of the i.c.r route, oral delivery is a desirable alternative route potentially 
allowing safe, simple, and rapid delivery. We hypothesized that if the vaccine is able to 
survive the passage to, and is not absorbed before reaching the large intestine, the 
vaccination should mimic the efficacy of i.c.r. vaccination. Accordingly, we designed a two-
part FS30D/PLGA nanoparticle-releasing microparticle system and showed that this novel 
system can bypass the small intestine and deliver orally administered vaccines highly 
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specifically into the large intestinal mucosa and induce almost equal protective immunity 
not only in the rectal but also vaginal mucosa.
Uncoated PLGA particles given orally either failed to traverse the stomach or reached only 
the small intestine, and did not elicit significant colonic responses, but only small intestinal 
immune responses. These results underline the need for combinatorial use of Eudragit 
FS30D and PLGA to ensure specific targeting of the large intestine by orally delivered 
vaccine. Our study also indicates that TLR ligand activity was maintained after 
encapsulation within PLGA, and thus, PLGA is an ideal delivery vehicle for vaccines 
containing TLR agonists.
Further, we designed a contrasting vaccine coated nanoparticle (L100-55/PLGA) that 
delivered antigen to and induced T cell responses in the small intestine selectively,, whereas 
conversely FS30D-coated vaccines induced responses in the large but not small intestine, 
providing a comparison of these sites for the first time with the same vaccine. Thus, we have 
made a fundamental discovery of cellular immune compartmentalization within the gut 
mucosal immune system, which is reminiscent of the sub-compartmentalized gut humoral 
immunity29, highlighting the need for site-specific delivery of vaccines to the large intestinal 
mucosa for protection against infections transmitted by the rectal or vaginal route, and we 
demonstrated a novel way to accomplish this via the more practical oral route. Our findings 
thus strengthen the conception that the common mucosal immune system is somehow sub-
compartmentalized.
There are many potential applications of our delivery technology beyond the vaccination 
against viral infection. This novel strategy is applicable for many forms of vaccines such as 
DNA, recombinant proteins, peptides, and a wide variety of adjuvants, and may be adapted 
in the development of vaccination strategies combating certain sexually transmitted 
infections caused by not only viruses but possibly also other types of pathogens. It also 
suggests a new approach to the development of a preventive or therapeutic vaccination 
against mucosal malignancies such as colorectal as well as cervical cancer. With this 
technology, in-depth study of the mucosal immunological subcompartmentalization between 
the large and small intestines can be easily conducted. For example, besides vaccination, one 
could use this approach to localize the site of induction of oral tolerance. The technology 
may be incorporated with other technologies to devise therapies in which selective targeting 
within the gut mucosa is needed.
Our targeted micro/nanoparticle system lends itself to practical large-scale clinical 
applications because of its 1) great stability in a dry-powder formulation; 2) easy shipment 
and storage without refrigeration, and long shelf life; and 3) economical large batch GMP 
processing. These features would be highly desired for effective industrial manufacturing 
and clinical management. PLGA is contained in several FDA-approved products. Although 
fine tuning of the formulation may be necessary to account for longer transit times in the gut 
of non-human primates and humans, as well as slightly higher pH values (around 7.3) in the 
distal small intestine of humans, this study demonstrates a promising proof of concept that 
this type of formulation may be practical and effective for oral vaccination to induce lower 
GI immunity without the need for intrarectal delivery. Capsules either coated with or 
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comprised of Eudragit have been investigated in humans for site-targeted release in the 
distal GI tract30–32. Clinical approaches would be extended to consider packaging PLGA 
nanoparticles with these colon-specific capsules, which may represent a preferable carrier 
for targeted colon vaccination in humans.
In conclusion, we have demonstrated functional immune compartmentalization of the gut 
mucosa and developed a nanoparticle-releasing microparticle oral delivery system and 
demonstrated that it is an easy, non-invasive vaccination strategy effective against viral 
infection occurring through the rectal or vaginal mucosa. Such a vaccination strategy would 
represent a conceptually novel approach to the development of vaccines against mucosal 
infections and potentially against mucosal cancers and to advanced study of 
immunobiological mechanisms involving mucosal compartmentalization.
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I.C.R. delivered nanoparticles enter the large intestinal mucosa and orally delivered FS30D/
PLGA nanoparticle-releasing microparticles selectively targets the large intestinal mucosa 
for uptake. (a) Colorectal mucosal uptake of PLGA nanoparticles after i.c.r. delivery of 
PLGA/FITC-BSA nanoparticles. Cells were isolated from the colorectum 3 days after 
administration and measured for fluorescence-positive cells. (P < 0.01 between PLGA/
FITC-BSA and PBS treated. Representative of three independent experiments, n = 12 15 per 
group). (b) Induction of antigen-specific colorectal mucosal T cells after i.c.r. delivery of 
PLGA nanoparticles encapsulating PCLUS3-18IIB and MALP2+poly(I:C)+CpG vaccine 
(PLGA/PeptAg+TLRL). Three weeks after one immunization, colorectal cells were isolated 
and measured for P18-I10 specific CD8+ T cells by tetramer staining. P < 0.01 between 
PLGA/PeptAg+TLRL and PLGA alone. Representative of two independent experiments. n 
= 10 per group. (c) Gut mucosal uptake of PLGA particles after oral delivery of FS30D/
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PLGA or L100-55/PLGA. Cells were isolated from the small and large intestine at day 2 for 
measurement of fluorescence-positive cells. **P < 0.02 on white bar indicates the difference 
from small intestine. ***P < 0.001 on black bar indicates the difference from the small 
intestine. n = 9 12 per group. (d) Representative examples of flow cytometry from 
experiments shown in c.
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Orally delivered FS30D-coated PLGA nanoparticle vaccine induces antigen-specific T cells 
in the large intestine, while L100-55-coated vaccine induces the T cells in the small 
intestine. (a) Activation of DC after 20-h incubation with supernatants from FS30D-coated 
PLGA containing PCLUS3-18IIIB+TLRL (FS30D/PLGA/PeptAg+TLRL), antigen (FS30D/
PLGA/PeptAg) or vaccine only (PeptAg+TLRL) dissolved in PBS at pH 7.4 for 16 h (upper 
panels). Intracellular IL-12 was measured by flow cytometry (n = 6 per group). The micro/
nanoparticles were also given orally and DC activation in vivo was assessed ex vivo (lower 
panels), n = 5 per group. (b–d) Induction of T cell responses after oral delivery of FS30D/
PLGA/PeptAg+TLRL or L100-55/PLGA/PeptAg+TLRL. Oral administration was 
conducted twice with a two-week interval. Tetramer positive cells in the colorectum (b and 
c) or upper part of the small intestine (d) were measured three weeks after. The i.c.r. group 
was immunized with vaccine only without nanoparticles but formulated in DOTAP. **P < 
0.01, ***P < 0.001 indicate the significant difference between the group with asterisks and 
each of the groups without asterisks. There are no differences between the two groups with 
asterisks. Representative of experiments (c) is summarized in b. In d, P < 0.001 for L100-55 
vs other groups. n = 8 12 per group. (e and f) T cell responses induced after oral delivery of 
uncoated or FS30D-coated PLGA/PeptAg+TLRL. Tetramer positive cells in the upper small 
intestine (e) or the colorectum (f) were measured. **P < 0.01 indicates the significant 
difference between groups (n = 7 per group).
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Orally delivered FS30D-coated PLGA nanoparticle peptide vaccine confers T-cell mediated 
resistance to virus infection in the rectal or vaginal tract. FS30D/PLGA/PeptAg+TLRL or 
L100-55/PLGA/PeptAg+TLRL was given orally to mice twice with a two-week interval, 
followed by i.c.r. (a) or i.vag. (b) challenge with 2×107 or 1×107 PFU of vPE16, 
respectively, three weeks after the last immunization. Ovaries (where this virus primarily 
replicates) were removed at day 6 for viral titer assessment. **P < 0.01, ***P < 0.001 
indicate the significant difference in viral titer between the group with asterisks and each of 
the groups without asterisks (n = 12 15 per group).
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Orally delivered FS30D-coated PLGA nanoparticle protein vaccine confers antibody-
mediated resistance to virus infection in the rectal or vaginal tract. FS30D-coated PLGA 
containing antigen proteins A33 and L1 and TLR ligands (ProtAg+TLRL) was administered 
orally with a two-week interval. (a) Serum and local IgA (top) and IgG (bottom) antibodies 
against both A33 and L1 (together) measured at three weeks after the last immunization. 
Both FS30D/PLGA/ProtAg+TLRL p.o. and ProtAg+TLRL i.c.r. groups have significantly 
higher antibody titers than the other groups (P < 0.02). **P < 0.01 and ***P < 0.001 
indicate difference (for both sites) from each of the bars without asterisks. Results from two 
independent experiments (n = 10 per group). (b) Disease course of the mice after challenge 
with WR by the i.c.r. (4×107 PFU) or i.vag. (1×107 PFU) route three weeks after the last 
immunization. **P < 0.02, ***P < 0.001 indicate the differences between the FS30D/
PLGA/ProtAg+TLRL and unimmunized groups in weight loss (n = 10 14 per group). §, 
75% mortality; ¶, 50% mortality.
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